Asset Dedication LLC maintained its position in Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,189 shares of the company’s stock at the end of the third quarter. Asset Dedication LLC’s holdings in Johnson & Johnson were worth $1,097,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. RNC Capital Management LLC increased its position in Johnson & Johnson by 3.6% in the third quarter. RNC Capital Management LLC now owns 204,384 shares of the company’s stock valued at $24,144,000 after buying an additional 7,142 shares during the period. Carlton Hofferkamp & Jenks Wealth Management LLC increased its position in Johnson & Johnson by 5.1% in the third quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 19,773 shares of the company’s stock valued at $2,335,000 after buying an additional 964 shares during the period. Trust Co. of Virginia VA boosted its stake in Johnson & Johnson by 2.3% in the third quarter. Trust Co. of Virginia VA now owns 99,467 shares of the company’s stock valued at $11,750,000 after buying an additional 2,216 shares in the last quarter. Somerset Trust Co boosted its stake in Johnson & Johnson by 9.0% in the third quarter. Somerset Trust Co now owns 28,717 shares of the company’s stock valued at $3,392,000 after buying an additional 2,382 shares in the last quarter. Finally, Berson & Corrado Investment Advisors LLC boosted its stake in Johnson & Johnson by 10.6% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 2,816 shares of the company’s stock valued at $333,000 after buying an additional 271 shares in the last quarter. 64.05% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.02% during midday trading on Friday, hitting $114.60. The company had a trading volume of 4,935,188 shares. The company has a market capitalization of $311.77 billion, a PE ratio of 20.12 and a beta of 0.72. The company has a 50-day moving average of $114.47 and a 200-day moving average of $118.28. Johnson & Johnson has a 12 month low of $94.28 and a 12 month high of $126.07.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The business earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same quarter in the prior year, the firm earned $1.49 earnings per share. The business’s revenue was up 4.2% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post $6.71 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 14th. Shareholders of record on Tuesday, February 28th will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, February 24th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.79%. Johnson & Johnson’s payout ratio is currently 56.64%.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at http://www.watchlistnews.com/johnson-johnson-jnj-stake-maintained-by-asset-dedication-llc/1061541.html.

Several analysts recently issued reports on the company. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, September 28th. Vetr cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $123.13 target price for the company. in a research report on Wednesday, September 21st. Credit Suisse Group reiterated a “neutral” rating and set a $123.00 target price on shares of Johnson & Johnson in a research report on Monday, September 19th. RBC Capital Markets set a $133.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Wednesday, November 9th. Finally, Jefferies Group reiterated a “hold” rating and set a $107.00 target price on shares of Johnson & Johnson in a research report on Tuesday, December 20th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $122.22.

In related news, Director Charles Prince purchased 875 shares of the company’s stock in a transaction dated Friday, October 21st. The stock was acquired at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the transaction, the director now directly owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.